Vaccine company Voltron Therapeutics Inc on Thursday announced a Sponsored Research Agreement with the Vaccine and Immunotherapy Center (VIC) of the Massachusetts General Hospital (MGH) to co-develop a new vaccine to protect patients against COVID-19.
Under the agreement, VIC's Self-Assembling Vaccine (SAV) platform will be licensed exclusively to Voltron for vaccine development. The vaccine is expected to enter animal testing by the end of April 2020 and will be followed by safety studies. The VaxCelerate platform was developed to improve patient outcomes by engaging the immune system to identify and target certain pathogens or cancer cells.
HaloVax, a special purpose subsidiary of Voltron Therapeutics Inc, will reportedly spearhead the development of new vaccine. Data on two candidates from both small and large animal models is expected within six months.
In the SAV programme, the vaccine incorporates a heat shock protein that activates the immune system in contrast to prior vaccine efforts, which used chemical adjuvants like alum. The vaccine consists of a fusion protein between a heat shock protein and Avidin. Biotinylated immunogenic peptides are then incorporated to customise the vaccine.
Norgine submits first marketing authorisation application submissions for approval of eflornithine
Innovent Biologics names new Oncology CMO
UroGen's UGN-103 IND accepted by FDA for bladder cancer treatment
Innate Pharma advances Sanofi-developed NK cell engager to Phase 2 for blood cancer patients
Portage Biotech expands evaluation of strategic alternatives
Stamford Pharmaceuticals starts locally advanced basal cell carcinoma (laBCC) trial of SP-002
QST selects RayStation for advanced carbon ion therapy
Candel Therapeutics granted FDA Orphan Drug Designation for CAN-2409 in pancreatic cancer treatment
Innate Pharma reports preclinical efficacy of IPH45
Roche attains CE Mark for first companion diagnostic for HER2-low metastatic breast cancer
BioCity Biopharma's BC2027 Phase one study IND application receives US FDA approval
enGene Holdings names new senior vice president, Urologic Oncology and Clinical Development
CLS secures second order from NIH Clinical Center for Thermal Therapy System accessories